Prospects for the use of bovhyaluronidase azoxymer in the post-COVID period after a severe COVID-19: A clinical case

Fibrotic changes in lung tissues after coronavirus disease 2019 (COVID-19) are receiving increasing attention. Current tasks for the medical community include not only minimizing the effects on etiotropic factors and increasing the bodys resistance to the damaging effects of viruses but also minimizing the number of complications and in the long term reducing morbidity and improving the prognosis and quality of life of patients after a severe viral infection. The aim of this study was to describe a clinical case of the effectiveness of bovhyaluronidase azoxymer in the post-COVID period after a severe COVID-19. A 46-year-old patient was diagnosed with COVID-19, which manifested as an acute respiratory viral infection in the clinic. She was hospitalized in a specialized department. Computed tomography noted 80% of lung damage, and oxygen saturation decreased to 70%. She was treated with antibiotics, antiviral drugs, anticoagulants, and hormones. After 1 month, she was discharged with improvement, and residual effects of lung damage (56%). In the post-hospital period, bovhyaluronidase azoximer for 25 days was prescribed. Clinical, radiological, laboratory, and clinical applied in a hospital. On computed tomography, no signs of infiltrative changes in the lungs and signs of pneumofibrosis, a picture of viral pneumonia, were noted. The case highlights the positive action of bovhyaluronidase azoxymer as an immunomodulatory and antifibrosing agent.